WHO informal consultation on the scientific basis of specifications for production and control of inactivated Japanese encephalitis vaccines for human use, Geneva, Switzerland, 1–2 June 2006

World Health Organization, 2006, Japanese encephalitis vaccines: WHO position paper, Weekly Epidemiol Rec, 81, 331 World Health Organization. Report of the bi-regional meeting on Japanese encephalitis (WHO SEA/WPR and PATH's JE Project). New Delhi, India, 2005. Tsai TF. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, October 13–15, 1998. Vaccine 2000;18 Suppl 2:1–25. Igarashi, 1992, Epidemiology and control of Japanese encephalitis, World Health Stat Q, 45, 299 Luo, 1994, The efficacy of Japanese encephalitis vaccine in Henan, China: a case-control study, Southeast Asian J Trop Med Public Health, 25, 643 Ding, 2003, Cost-effectiveness of routine immunization to control Japanese encephalitis in Shanghai, China, Bull World Health Organ, 81, 334 Siraprapasiri, 1997, Cost benefit analysis of Japanese encephalitis vaccination program in Thailand, Southeast Asian J Trop Med Public Health, 28, 143 World Health Organization. Requirements for Japanese encephalitis vaccine (inactivated) for human use. In: WHO Expert Committee on Biological Standardization, vol. Thirty-eighth report. Geneva: World Health Organization; 1988. Hombach J, Solomon T, Kurane I, Jacobson J, Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, September 2–3, 2004. Vaccine 2005;23(45):5205–11. World Health Organization, 2003, Guidelines on transmissible spongiform encephalopathies in relation to biological and pharmaceutical products World Health Organization. Procedure for assessing the acceptability, in principle, of vaccines for purchase by United Nations agencies. WHO/IVB/05.19. http://www.who.int/vaccines-documents/DocsPDF06/812.pdf. 2006. World Health Organization. National regulatory authorities. http://www.who.int/immunization_standards/national_regulatory_authorities%20/role/en/index.html/. accessed May 1, 2007. World Health Organization. Developing Countries’ Vaccine Regulators Network Establishment. http://www.who.int/immunization_standards/vaccine_regulation/dcvrn/en/index.html/. accessed May 1, 2007. World Health Organization. Global Advisory Committee on Vaccine Safety (GACVS). http://www.who.int/vaccine_safety/en/. accessed May 1, 2007. World Health Organization. Guidelines for the production and control of Japanese encephalitis vaccine (live) for human use. In: WHO Expert Committee on Biological Standardization vol. Fifty-first report. Geneva: World Health Organization; 2002. World Health Organization. Requirements for the use of animal cells as in vitro substrates for the production of biologicals (requirements for biological substances no. 50). In: WHO Expert Committee on Biological Standardization vol. Forty-seventh report. Geneva: World Health Organization; 1998. World Health Organization. Requirements for the use of animal cells as in vitro substrates for the production of biologicals (addendum 2003). In: WHO Expert Committee on Biological Standardization vol. Fifty-fourth report. Geneva: World Health Organization; 2005. Hoke, 1988, Protection against Japanese encephalitis by inactivated vaccines, N Engl J Med, 319, 608, 10.1056/NEJM198809083191004 Hammon, 1973, Passive immunity for arbovirus infection. I. Artificially induced prophylaxis in man and mouse for Japanese (B) encephalitis, Am J Trop Med Hyg, 22, 524, 10.4269/ajtmh.1973.22.524